FGFR2 mutation in endometrial carcinoma (~10-12% endometrioid histology). Pemigatinib and...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-FGFR2-MUTATION-ENDOMETRIAL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-ENDOMETRIAL |
| Sources | SRC-CIVIC SRC-ESGO-ENDOMETRIAL-2025 SRC-NCCN-UTERINE-2025 |
Actionability Facts
| Biomarker | BIO-FGFR2 |
|---|---|
| Variant | activating mutation (~12% endometrioid; hotspots S252W, N549K, K310R) |
| Disease | DIS-ENDOMETRIAL |
| ESCAT tier | IIA |
| Recommended combinations | pemigatinib (basket trial / NCI-MATCH for FGFR2-mutant endometrial), erdafitinib (basket trial) |
| Evidence summary | FGFR2 mutation in endometrial carcinoma (~10-12% endometrioid histology). Pemigatinib and erdafitinib have basket activity (FIGHT-207, Mirati / NCI-MATCH EAY131-W) — ORR ~25-30% in FGFR2-mutant endometrial. No regulatory approval for endometrial alone; tumor-agnostic FGFR-TKI label not yet granted. |
Notes
ESCAT IIA. OncoKB Level 3A. Standard advanced/recurrent endometrial 1L is carboplatin + paclitaxel ± dostarlimab (RUBY) / pembrolizumab (NRG-GY018) for dMMR or pMMR. FGFR2 testing reserved for trial enrollment / panel-detected. Trial-source gap: SRC-FIGHT-207 not yet ingested.
Used By
No reverse references found in the YAML corpus.